Results

Total Results: 406 records

Showing results for "company".

61. uterine-fibroids-protocol-160301 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/uterine-fibroids_research-protocol.pdf
    March 01, 2016 - uterine fibroid treatment Drug  Category   Drug  Name   Brand/Other  Names   Labeled  Indications   Company … online: March 1, 2016 20   Drug  Category   Drug  Name   Brand/Other  Names   Labeled  Indications   Company …     Non-­FDA  labeled  indications:   Disorder  of  the  cardiovascular  system   Eli  Lilly  and  Company

62. PEPTIC ULCER #11 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pepticulcer_hi_impact.pdf
    January 01, 2012 - therapy, the patient mixes the ova with juice or an electrolyte drink and swallows the solution. 3 The company … titration to a 1,000 ova per dose if no response is seen after 8 weeks (four treatments). 3 The company … The company requires a letter from a physician and a statutory declaration from the importer stating … that the worms are for personal use and constitute 3 or fewer months of treatment. 4 The company then

63. Diabetes Mellitus (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - The company also reported that 60 patients in FREEDOM-1 HBL had a 3.4% mean reduction in HbA1c, with … (We believe the results for HbA1c that the company stated as percent changes should instead be expressed … The company reported that tolerability was similar between the 40 mcg per day and the higher 60 mcg … According to the company, “the new Enlite Serter provides a simpler sensor insertion process with a … The company reported that more subjects in the insulin aspart group achieved the HbA1c target of 7%

64. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicine-safety-call-center_research.pdf
    September 01, 2007 - Cover Page An Information Technology Architecture for Drug Effectiveness Reporting and Post-Marketing Surveillance Amar Gupta Eller College of Management The University of Arizona gupta@eller.arizona.edu Ray Woosley The Critical Path Institute 4280 N. Campbell Ave. #214 Tucson, AZ 85718 Rwo…

65. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/it-architecture-for-post-marketing-surveillance-arizona-cert.pdf
    September 01, 2007 - Cover Page An Information Technology Architecture for Drug Effectiveness Reporting and Post-Marketing Surveillance Amar Gupta Eller College of Management The University of Arizona gupta@eller.arizona.edu Ray Woosley The Critical Path Institute 4280 N. Campbell Ave. #214 Tucson, AZ 85718 Rwo…

66. Crosscutting-Horizon-Scan-High-Impact-1406 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - The company received FDA marketing clearance for the monitoring device in March 2010 and for the ingestible … The company is working with selected pharmaceutical manufacturers to choose medications for sensor … In August 2010, the company received Conformité Européene (CE) mark approval to market the complete … system in the European Union.34 The company announced collaborations with Novartis International AG … Clinical Pathway at Point of This Intervention The company states that tablets can be delivered to patients

67. Infectious Disease Including HIV/AIDS #09 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1512.pdf
    January 28, 2016 - Bristol-Myers Squibb Company. … New York (NY): Bristol- Myers Squibb Company; 2015 Jul. 8 p. … Princeton (NJ): Bristol-Myers Squibb Company; 2014 Apr 7 [accessed 2014 May 15]. [3 p]. … New York (NY): Bristol-Myers Squibb Company; 2015 Apr 25 [accessed 2015 May 06]. [4 p]. … Princeton (NJ): Bristol-Myers Squibb Company; 2015 Oct 6 [accessed 2015 Nov 25]. [5 p].

68. Slide 1
    effectivehealthcare.ahrq.gov/sites/default/files/selection-of-data-sources-chapter-8.pptx
    January 01, 2013 - Claims submitted to the insurance company use the National Drug Code (NDC) as the identifier of the product

69. Diabetes Mellitus (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1312.pdf
    January 01, 2016 - In November 2011, the company stated the following about the complete response letter it received from … The company met with FDA in June 2012 and based on the outcome of that meeting, declared intentions … San Diego (CA): Eli Lilly and Company; 2011 June 24 [accessed 2013 Jun 12]. [4 p]. … Indianapolis (IN): Eli Lilly and Company; 2011 Aug 10 [accessed 2011 Aug 18]. [3 p]. … Indianapolis (IN): Eli Lilly and Company; 2011 Nov 8 [accessed 2011 Nov 11]. [3 p].

70. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity_hi_impact.pdf
    April 17, 2012 - EndoBarrier device were recently published and new results from three studies were reported by the company … The company intends to submit a premarket approval application to FDA, pending outcomes of ongoing … EndoBarrier device were recently published, 53,56 and new results from three studies were reported by the company … in its therapeutic goods registry for treatment of T2DM and obesity for up to 12 months. 58 The company

71. Disposition of Comments Report for Multigene Panels in Prostate Cancer Risk Assessment (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-risk-assessment-genes_disposition-comments.pdf
    July 03, 2012 - Disposition of Comments Report for Multigene Panels in Prostate Cancer Risk Assessment Source: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and- reports/?pageaction=displayproduct&productID=1171 Published Online: July 3, 2012 Comparative Effectiveness Research Review Disposition of Comme…

72. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
    December 01, 2013 - The company calls it a “living organ” transplant. … Although ivacaftor’s price is considered to be the highest-cost drug therapy on the market today, the company … the time an organ is maintained outside the body in good condition before transplantation.55 The company

73. Research White Paper Registries in Accountable Care Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/accountable-care-registries-guide-3rd-ed-addendum-white-paper-2018-5.pdf
    January 01, 2018 - (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No … (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No … (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No

74. nnovative Methods in Stakeholder Engagement: An Environmental Scan (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/stakeholders-engagement-others_research-2012-1.pdf
    January 01, 2012 - environmentally more satisfactory Improve internal management practices among all parts of the company … are paid £150 per day, plus expenses; and it is managed at arm’s length from NICE by Vision 21, a company … An interviewee from a nationwide research and polling company similarly defined an innovative approach … Retrieved May 3, 2011, from http://www.healthtalkonline.org/ Hewlett-Packard Development Company. ( … and public health issues Alliance Health Network http://www.alliancehealth.org Technology-driven company

75. Health Insurance | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/health-topics/health-insurance

76. VU EPC DBD Protocol_AHRQ comments_revised_clean (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/disruptive-behavior-disorder_research-protocol.pdf
    January 30, 2014 - List of pharmacologic agents for SIP Drug Company Anticonvulsants Carbamazepine (Tegretol®) Novartis … Lurasidone (Latuda®) Sunovion Pharmaceuticals Inc., Marlborough, MA Olanzapine (Zyprexa®) Eli Lilly and Company … , Indianapolis, IN Olanzapine/Fluoxetine (Symbyax®) Eli Lilly and Company, Indianapolis, IN Paliperidone … Ziprasidone (Geodon®) Pfizer Roerig, New York, NY Beta-blockers Propranolol Mutual Pharmaceutical Company … Drug Company

77. American Medical Association (AMA) App Challenge and AMA Idealab (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/eaagleston.pdf
    May 29, 2025 - American Medical Association (AMA) App Challenge and AMA Idealab INNOVATIONS CONFERENCE -- AMA SPEAKERS: ROBERT HICKS, BUSINESS PROCESS DEVELOPMENT DIRECTOR, AMA BRIAN EAGGLESTON, PHYSICIAN OUTREACH AND RETENTION, AMA HICKS: I'm Bob Hicks. I'm business process development director …

78. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ischemic-stroke-treatment_executive.pdf
    January 01, 2011 - Neurothrombectomy devices in use Company In Clinical Device Class Name FDA Indication Use? … Neurothrombectomy devices in use (continued) Company In Clinical Device Class Name FDA Indication Use

79. Disposition of Comments_Comparative Effectiveness Review No. 272_Genitourinary Syndrome of Menopause: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-272-genitourinary-syndrome-disposition-comments.pdf
    July 31, 2024 - Our company is in the process of developing a FDA Breakthrough Designated ultrasound to treat the vaginal

80. Prostate-Cancer-Risk-Assessment-Genes Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-risk-assessment-genes_executive.pdf
    July 01, 2012 - Evidence-Based Practice Evidence-based Practice Program The Agency for Healthcare Research and Quality (AHRQ), through its Evidence- based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to imp…